PURE Bioscience Reports Fiscal 2022 Third Quarter and Nine-Month Financial Results
Update on Business Segments and PURE’s SDC-Based Antimicrobial Solutions RANCHO CUCAMONGA, Calif.–(BUSINESS WIRE)–PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2022. Q3: Summary of Results of Operations Net product sales for the fiscal … [Read more…]